Lupus Anticoagulant Detection under the Magnifying Glass

被引:6
作者
Molinari, Angelo Claudio [1 ]
Martini, Tiziano [2 ]
Banov, Laura [1 ]
Ierardi, Antonella [3 ]
Leotta, Marzia [3 ]
Strangio, Alessandra [3 ]
Santoro, Rita Carlotta [3 ]
机构
[1] IRCCS Ist Giannina Gaslini, Thrombosis & Hemostasis Unit, I-16147 Genoa, Italy
[2] Cesena Gen Hosp, Ctr Congenital Bleeding Disorders, Immuno Haematol & Transfus Med, I-47521 Cesena, Italy
[3] Azienda Osped Univ Dulbecco, Hemostasis & Thrombosis Unit, I-88100 Catanzaro, Italy
关键词
lupus anticoagulant; antiphospholipid antibody syndrome; thrombosis; anticoagulation; activated partial thromboplastin time; FACTOR-VIII ANTIBODIES; PARTIAL THROMBOPLASTIN TIME; DILUTE PROTHROMBIN TIME; TEST-SPECIFIC CUTOFF; SNAKE-VENOM TIME; ASYMPTOMATIC CARRIERS; LABORATORY DIAGNOSIS; ORAL ANTICOAGULANTS; CLOTTING TIME; TESTS;
D O I
10.3390/jcm12206654
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis and/or pregnancy morbidity), combined with persistently circulating antiphospholipid antibodies (aPL). Lupus anticoagulant (LA) is one of the three laboratory parameters (the others being antibodies to either cardiolipin or beta 2-glycoprotein I) that defines this rare but potentially devastating condition. For the search for aCL and a beta 2-GP-I, traditionally measured with immunological solid-phase assays (ELISA), several different assays and detection techniques are currently available, thus making these tests relatively reliable and widespread. On the other hand, LA detection is based on functional coagulation procedures that are characterized by poor standardization, difficulties in interpreting the results, and interference by several drugs commonly used in the clinical settings in which LA search is appropriate. This article aims to review the current state of the art and the challenges that clinicians and laboratories incur in the detection of LA.
引用
收藏
页数:19
相关论文
共 110 条
[1]  
AICE (Associazione Italiana Centri Emofilia) Quality Laboratory Working Group, 2022, Consensus Document: Procedures for Hemostasis Laboratory, Mixing Test and Measurement of Factors VIII and IX
[2]   Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting [J].
Antovic, Aleksandra ;
Norberg, Eva-Marie ;
Berndtsson, Maria ;
Rasmuson, Agnes ;
Malmstrom, Rickard E. ;
Skeppholm, Mika ;
Antovic, Jovan .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (09) :1700-1704
[3]   An approach to factor assays in patients with strong lupus anticoagulants [J].
Armitage, J ;
Ashcraft, J ;
Kim, A ;
Kaplan, HS .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1995, 1 (02) :125-130
[4]  
Bailly J., 2020, J. Med. Lab. Sci. Technol. South. Afr, V2, P6, DOI [10.36303/JMLSTSA.2020.2.1.39, DOI 10.36303/JMLSTSA.2020.2.1.39, DOI 10.1002/RTH2.12006]
[5]   DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples [J].
Baker, Steven Andrew ;
Jin, Jing ;
Pfaffroth, Christopher ;
Vu, Trang ;
Zehnder, James L. .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (02) :314-325
[6]  
Blanco AN, 2000, HAEMATOLOGICA, V85, P1045
[7]  
Blanco AN, 2002, HAEMATOLOGICA, V87, P271
[8]   Factor VIII Activity and Inhibitor Assays in the Diagnosis and Treatment of Hemophilia A [J].
Castellone, Donna D. ;
Adcock, Dorothy M. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2017, 43 (03) :320-330
[9]   Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity [J].
Cattini, Maria Grazia ;
Bison, Elisa ;
Pontara, Elena ;
Cheng, Chunyan ;
Denas, Gentian ;
Pengo, Vittorio .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (05) :1124-1132
[10]  
Cervera R, 2017, THROMB RES, V151, pS43, DOI 10.1016/S0049-3848(17)30066-X